Voloridge Investment Management
QNCX icon

Voloridge Investment Management’s Quince Therapeutics QNCX Stock Holding History

Voloridge Investment Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,130
Closed -$2.64M – 1601
2022
Q1 		$2.64M Sell
2,130
-101
-5% -$137K 0.02% 857
2021
Q4 		$5.63M Buy
2,231
+1,883
+541% +$11.5M 0.03% 680
2021
Q3 		$6.37M Buy
348
+182
+110% +$2.89M 0.04% 585
2021
Q2 		$1.76M Buy
+166
New +$1.39M 0.01% 1035
2021
Q1 		– Sell
-164
Closed -$910K – 1611
2020
Q4 		$910K Buy
+164
New +$1.45M 0.01% 995

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Voloridge Investment Management's QNCX Position: Q2 2022 in Review

Voloridge Investment Management sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 2,130 shares — an estimated $2.64M sold.

Voloridge Investment Management first reported a position in QNCX in Q4 2020 and held it in 5 quarters. The position peaked at $6.37M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Voloridge Investment Management reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 2,130 Quince Therapeutics shares in Q2 2022, an estimated $2.64M.
  • Voloridge Investment Management first reported a position in Quince Therapeutics in Q4 2020 and held it in 5 quarters.
  • Voloridge Investment Management's Quince Therapeutics position peaked at $6.37M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Voloridge Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.